1-BOC-4-哌啶甲酰肼 | 187834-88-4

• 物质功能分类: 有机原料 - 肼或胲的有机衍生物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-BOC-4-哌啶甲酰肼
• 中文别名: 1-Boc-哌啶甲酸肼；1-叔丁氧羰基-4-哌啶甲酰肼；N-BOC-4-哌啶甲酰肼
• 英文名称: tert-butyl 4-(hydrazinecarbonyl)piperidine-1-carboxylate
• 英文别名: 4-hydrazinocarbonylpiperidine-1-carboxylic acid tert-butyl ester；1-Boc-Isonipecotic acid hydrazide
• CAS: 187834-88-4
• 化学式: C₁₁H₂₁N₃O₃
• mdl: MFCD06795927
• 分子量: 243.306
• InChiKey: JLIKTOWFNQDEME-UHFFFAOYSA-N

物化性质

• 熔点：
  104-106°C
• 沸点：
  409.2±34.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Boc-isonipecotic acid hydrazide
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-isonipecotic acid hydrazide
CAS number: 187834-88-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H21N3O3
Molecular weight: 243.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

N-Boc-4-哌啶甲酸乙酯是合成钠通道阻滞剂的关键中间体，用于治疗脑卒中患者。此外，它也用作制备肿瘤坏死因子转化酶抑制剂的关键中间体，并且还是合成1-BOC-4-哌啶甲酰肼的重要前体。

制备

以N-Boc-4-哌啶甲酸乙酯或N-Boc-4-哌啶甲酸甲酯为起始物料，通过与水合肼或双(1H-咪唑-2-基)-甲酮的反应可制备得到目标化合物1-BOC-4-哌啶甲酰肼。1-BOC-4-哌啶甲酰肼的合成反应式如图1所示：

反应信息

• 作为反应物：
  描述：

  1-BOC-4-哌啶甲酰肼 在 盐酸 、 水 、 sodium cyanoborohydride 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 、 甲醇 为溶剂， 反应 19.0h， 生成 7-(2,4-dichlorophenyl)-2-(1-methylpiperidin-4-yl)[1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-one
  参考文献：
  名称：

  SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES

  摘要：

  这项发明涉及取代咪唑基和三唑基嘧啶、咪唑基和吡唑基吡嗪以及咪唑基三嗪，以及它们的制备方法，以及它们用于制造用于治疗和/或预防疾病的药物，特别是血液疾病，最好是白细胞减少症和中性粒细胞减少症。

  公开号：

  US20110144131A1
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸甲酯 在 肼 作用下， 以 甲醇 为溶剂， 生成 1-BOC-4-哌啶甲酰肼
  参考文献：
  名称：

  新型1,2,4-恶二唑及其类似物的合成作为潜在的抗癌药

  摘要：

  合成了3,5-二取代-1,2,4-恶二唑7–9及其生物等效物1,3,4-恶二唑14和1,3,4-噻二唑16的文库，并对其体外抗癌性进行了评估。对一组六种人类癌细胞系的潜力。合成恶二唑7–9的关键步骤包括将of胺肟6与适当的羧酸偶联，然后进行热环化。由常见的前体二酰基肼13的反应制备生物甾体1,3,4-恶二唑14和1,3,4-噻二唑16分别使用亚硫酰氯和Lawesson试剂。对合成化合物的抗癌研究表明，在C-3芳基环上存在环戊氧基或正丁氧基，在1,2,4-恶二唑的C-5位置上存在哌啶-4-基或三氯甲基是必不可少的。活动。尤其是1,2,4-恶二唑7i和类似物1,3,4-噻二唑16分别显示出对DU145（IC 50：9.3μM）和MDA-MB-231（IC 50：9.2μM）细胞系的显着活性。。

  DOI：

  10.1016/j.ejmech.2011.03.031

文献信息

• [EN] INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉ D'INDAZOLE ET PYRROLOPYRIDINE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI
  申请人：DAINIPPON SUMITOMO PHARMA CO

  公开号：WO2012169649A1

  公开（公告）日：2012-12-13

  The present invention relates to a novel indazole- or pyrrolopyridine-derivative, represented by the formula (1) below, that has an agonistic action or a partial agonistic action against serotonin-4 receptor, and a pharmaceutical composition comprising the same. Formula (1) [wherein each substituent is as defined in claim 1]

  本发明涉及一种新型吲唑基或吡咯吡啶基衍生物，由下面的式（1）表示，该衍生物对5-羟色胺-4受体具有激动作用或部分激动作用，并且包括含有该衍生物的药物组合物。式（1）[其中每个取代基如权利要求1所定义]
• [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：NOVARTIS AG

  公开号：WO2013012723A1

  公开（公告）日：2013-01-24

  The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

  本发明提供了式(I)的化合物，其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物，以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途，包括但不限于癌症。
• [EN] AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE<br/>[FR] INHIBITEURS DE L'AUTOTAXINE CONTENANT UN NOYAU À CYCLE BENZYLE-AMIDE CYCLIQUE HÉTÉROAROMATIQUE
  申请人：NOVARTIS AG

  公开号：WO2015008230A1

  公开（公告）日：2015-01-22

  The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

  本发明涉及新型化合物，这些化合物是自体磷脂酶抑制剂，涉及它们的制备方法，含有它们的药物组合物和药物，以及它们在由自体磷脂酶介导的疾病和紊乱中的应用。
• [EN] 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA<br/>[FR] 1,2,4-TRIAZOLES COMME MODULATEURS ALLOSTÉRIQUES DE L'ACTIVITÉ DES RÉCEPTEURS MGLU5 POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE OU DE LA DÉMENCE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013083741A1

  公开（公告）日：2013-06-13

  This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

  这项发明涉及公式（I）化合物的用途，它们作为mGlu5受体活性的正变构调节剂，包含这些化合物的药物组合物，以及使用它们作为治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的方法，如精神分裂症或认知衰退，例如痴呆或认知障碍。A、B、X、R1、R2、R3的含义在描述中给出。
• [EN] N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE<br/>[FR] DÉRIVÉS N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-MÉTHYLPROPIONYL)-PIPÉRIDINE EN TANT QU'INHIBITEURS DE PYRUVATE DÉSHYDROGÉNASE KINASE
  申请人：MERCK PATENT GMBH

  公开号：WO2015090496A1

  公开（公告）日：2015-06-25

  Compounds of the formula (I) in which R, R1 and R3 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

  公式(I)中的化合物，其中R、R1和R3的含义如权利要求1所述，是丙酮酸脱氢酶激酶（PDHK）的抑制剂，可以用于治疗诸如癌症等疾病。